Citigroup Maintains Neutral on Establishment Labs Hldgs, Lowers Price Target to $50
Establishment Labs Hldgs Analyst Ratings
Establishment Labs Hldgs Analyst Ratings
Mizuho Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $70
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Establishment Labs Hldgs Analyst Ratings
Citi: Downgraded the rating of Investing Labs Hldgs (ESTA.US) from buying to neutral, and the target price was adjusted from $60.00 to $60.00.
Citigroup Downgrades Establishment Labs Holdings to Neutral From Buy With $60 Price Target
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Cytokinetics (CYTK)
Establishment Labs Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gritstone Oncology (GRTS)
Establishment Labs Hldgs Analyst Ratings
Mizuho Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $65
TD Cowen Adjusts Establishment Labs Price Target to $60 From $50, Maintains Outperform Rating
Establishment Labs Hldgs Analyst Ratings
Buy Rating Affirmed for Establishment Labs on Positive FDA Approval Progress and Strong GMP Preparedness
JP Morgan Maintains Overweight on Establishment Labs Hldgs, Raises Price Target to $53
Establishment Labs Hldgs Analyst Ratings
Establishment Labs Holdings: A Promising Buy Rating With Strategic Growth and Market Expansion